BE1004051A4 - Solution injectable et procede pour la preparer. - Google Patents
Solution injectable et procede pour la preparer. Download PDFInfo
- Publication number
- BE1004051A4 BE1004051A4 BE9001046A BE9001046A BE1004051A4 BE 1004051 A4 BE1004051 A4 BE 1004051A4 BE 9001046 A BE9001046 A BE 9001046A BE 9001046 A BE9001046 A BE 9001046A BE 1004051 A4 BE1004051 A4 BE 1004051A4
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- bis
- alkaloid
- zinc
- aqueous solution
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 239000007924 injection Substances 0.000 title abstract description 6
- 238000002347 injection Methods 0.000 title abstract description 6
- 239000000243 solution Substances 0.000 title description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 19
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000011701 zinc Substances 0.000 claims abstract description 16
- 229910052751 metal Inorganic materials 0.000 claims abstract description 13
- 239000002184 metal Substances 0.000 claims abstract description 13
- 239000003755 preservative agent Substances 0.000 claims abstract description 12
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims abstract description 11
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims abstract description 10
- 229940050410 gluconate Drugs 0.000 claims abstract description 10
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims abstract description 9
- 229930013930 alkaloid Natural products 0.000 claims abstract description 9
- 230000002335 preservative effect Effects 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 5
- 229960004528 vincristine Drugs 0.000 claims abstract description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims abstract description 3
- 239000007864 aqueous solution Substances 0.000 claims description 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 15
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- 239000004227 calcium gluconate Substances 0.000 claims description 7
- 235000013927 calcium gluconate Nutrition 0.000 claims description 7
- 229960004494 calcium gluconate Drugs 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 229960005069 calcium Drugs 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 239000001755 magnesium gluconate Substances 0.000 claims description 5
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 5
- 229960003035 magnesium gluconate Drugs 0.000 claims description 5
- 235000011478 zinc gluconate Nutrition 0.000 claims description 5
- 239000011670 zinc gluconate Substances 0.000 claims description 5
- 229960000306 zinc gluconate Drugs 0.000 claims description 5
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 229960003415 propylparaben Drugs 0.000 claims description 4
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 229960002110 vincristine sulfate Drugs 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229940091250 magnesium supplement Drugs 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 claims description 2
- 229960004982 vinblastine sulfate Drugs 0.000 claims description 2
- -1 alkaloid salt Chemical class 0.000 claims 4
- 235000009529 zinc sulphate Nutrition 0.000 claims 1
- 239000011686 zinc sulphate Substances 0.000 claims 1
- TYGUTURXHKSOBP-UHFFFAOYSA-N 10-bromo-5,12-dihydroindolo[2,3-g]carbazole-2,3-diol Chemical compound C1=C(Br)C=C2NC3=C(C4=C(C=C(C(=C4)O)O)N4)C4=CC=C3C2=C1 TYGUTURXHKSOBP-UHFFFAOYSA-N 0.000 abstract description 6
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 229960003048 vinblastine Drugs 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 abstract description 2
- FFRFGVHNKJYNOV-DOVUUNBWSA-N 3',4'-Anhydrovinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C=C(C2)CC)N2CCC2=C1NC1=CC=CC=C21 FFRFGVHNKJYNOV-DOVUUNBWSA-N 0.000 abstract 1
- 229950001104 anhydrovinblastine Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 8
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 5
- 229910021653 sulphate ion Inorganic materials 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 4
- 239000007972 injectable composition Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 150000004688 heptahydrates Chemical class 0.000 description 3
- 229940102223 injectable solution Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 125000005274 4-hydroxybenzoic acid group Chemical class 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000012954 congenital vertebral-cardiac-renal anomalies syndrome Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Press Drives And Press Lines (AREA)
- Press-Shaping Or Shaping Using Conveyers (AREA)
- Powder Metallurgy (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU895804A HU204995B (en) | 1989-11-07 | 1989-11-07 | Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE1004051A4 true BE1004051A4 (fr) | 1992-09-15 |
Family
ID=10970758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE9001046A BE1004051A4 (fr) | 1989-11-07 | 1990-11-07 | Solution injectable et procede pour la preparer. |
Country Status (37)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4776843B2 (ja) | 1999-10-01 | 2011-09-21 | イムノゲン インコーポレーティッド | 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法 |
| JP2002100303A (ja) * | 2000-09-20 | 2002-04-05 | Hitachi Ltd | カラ−陰極線管 |
| US20050170015A1 (en) * | 2000-10-31 | 2005-08-04 | Brown Dennis M. | Antiproliferative colchicine compositions and uses thereof |
| FR2863891B1 (fr) * | 2003-12-23 | 2006-03-24 | Pf Medicament | Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation |
| US20110015221A1 (en) * | 2003-12-23 | 2011-01-20 | Pierre Fabre Medicament | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
| US8512761B2 (en) * | 2006-01-27 | 2013-08-20 | Yale University | Fast acting inhibitor of gastric acid secretion |
| TWI678213B (zh) * | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD155034A1 (de) * | 1980-07-31 | 1982-05-12 | Uwe Olthoff | Verfahren zur herstellung stabiler kalziumhaltiger injektionsloesungen |
| DE3324964A1 (de) * | 1982-07-19 | 1984-01-19 | Eli Lilly and Co., 46285 Indianapolis, Ind. | Waessrige pharmazeutische formulierung auf basis eines vincaalkaloids |
| GB2165540A (en) * | 1984-10-16 | 1986-04-16 | Richter Gedeon Vegyeszet | Metal complexes of bis-indole compounds and aqueous pharmaceutical compositions containing them |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4619935A (en) * | 1983-03-17 | 1986-10-28 | Eli Lilly And Company | Stable oncolytic formulations |
| FR2597750B1 (fr) * | 1986-04-25 | 1989-06-02 | Pf Medicament | Solution aqueuse stable de sulfate de vincristine |
| IL83086A (en) * | 1987-07-06 | 1991-03-10 | Teva Pharma | Stable,injectable solutions of vincristine salts |
| US4923876A (en) * | 1988-04-18 | 1990-05-08 | Cetus Corporation | Vinca alkaloid pharmaceutical compositions |
-
1989
- 1989-11-07 HU HU895804A patent/HU204995B/hu not_active IP Right Cessation
-
1990
- 1990-11-02 SK SK5402-90A patent/SK278421B6/sk unknown
- 1990-11-02 US US07/608,481 patent/US5397784A/en not_active Expired - Fee Related
- 1990-11-02 CZ CS905402A patent/CZ279433B6/cs not_active IP Right Cessation
- 1990-11-05 CH CH3499/90A patent/CH682130A5/de not_active IP Right Cessation
- 1990-11-05 ZA ZA908855A patent/ZA908855B/xx unknown
- 1990-11-06 DE DE4035253A patent/DE4035253B4/de not_active Expired - Fee Related
- 1990-11-06 IL IL9624990A patent/IL96249A/en unknown
- 1990-11-06 NL NL9002412A patent/NL9002412A/nl active Search and Examination
- 1990-11-06 IE IE399390A patent/IE62387B1/en not_active IP Right Cessation
- 1990-11-06 YU YU209590A patent/YU48373B/sh unknown
- 1990-11-06 AT AT0223090A patent/AT401469B/de not_active IP Right Cessation
- 1990-11-06 SE SE9003523A patent/SE509715C2/sv not_active IP Right Cessation
- 1990-11-06 DK DK266390A patent/DK266390A/da not_active Application Discontinuation
- 1990-11-06 UA UA4831830A patent/UA13162A/uk unknown
- 1990-11-06 RU SU4831830A patent/RU1828401C/ru active
- 1990-11-06 CA CA002029368A patent/CA2029368C/en not_active Expired - Fee Related
- 1990-11-06 NO NO904821A patent/NO175565C/no unknown
- 1990-11-06 PT PT95810A patent/PT95810B/pt active IP Right Grant
- 1990-11-06 IT IT06786890A patent/IT1242724B/it active IP Right Grant
- 1990-11-07 MY MYPI90001962A patent/MY104595A/en unknown
- 1990-11-07 AU AU65845/90A patent/AU638504B2/en not_active Ceased
- 1990-11-07 CN CN90109756A patent/CN1053569C/zh not_active Expired - Fee Related
- 1990-11-07 FI FI905508A patent/FI100455B/fi not_active IP Right Cessation
- 1990-11-07 NZ NZ236005A patent/NZ236005A/en unknown
- 1990-11-07 JP JP2300023A patent/JP3042702B2/ja not_active Expired - Fee Related
- 1990-11-07 PL PL90287663A patent/PL164881B1/pl not_active IP Right Cessation
- 1990-11-07 KR KR1019900017973A patent/KR0164601B1/ko not_active Expired - Fee Related
- 1990-11-07 AR AR90318325A patent/AR245592A1/es active
- 1990-11-07 BE BE9001046A patent/BE1004051A4/fr not_active IP Right Cessation
- 1990-11-07 BG BG93175A patent/BG60609B1/bg unknown
- 1990-11-07 GB GB9024222A patent/GB2238241B/en not_active Expired - Fee Related
- 1990-11-07 FR FR9013786A patent/FR2653998B1/fr not_active Expired - Fee Related
- 1990-11-07 ES ES9002834A patent/ES2026062A6/es not_active Expired - Lifetime
- 1990-11-07 GR GR900100795A patent/GR1001041B/el not_active IP Right Cessation
-
1993
- 1993-05-06 LT LTIP512A patent/LT3334B/lt not_active IP Right Cessation
- 1993-06-15 LV LVP-93-585A patent/LV10687B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD155034A1 (de) * | 1980-07-31 | 1982-05-12 | Uwe Olthoff | Verfahren zur herstellung stabiler kalziumhaltiger injektionsloesungen |
| DE3324964A1 (de) * | 1982-07-19 | 1984-01-19 | Eli Lilly and Co., 46285 Indianapolis, Ind. | Waessrige pharmazeutische formulierung auf basis eines vincaalkaloids |
| GB2165540A (en) * | 1984-10-16 | 1986-04-16 | Richter Gedeon Vegyeszet | Metal complexes of bis-indole compounds and aqueous pharmaceutical compositions containing them |
Non-Patent Citations (1)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 97, no. 20, 1982, page 388, résumé no. 168948s, Columbus, Ohio, US; & DD-A1-155 034 (U. OLTHOFF et al.) 12-05-1982 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0977562B1 (en) | Methods and compositions for delivery of taxanes | |
| CA2234140C (fr) | Formulation pharmaceutique lyophilisee stable | |
| CA2102778C (fr) | Nouvelles compositions a base de derives de la classe des taxanes | |
| EP0858329B1 (fr) | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation | |
| KR860001503B1 (ko) | 이버멕틴의 수용화 방법 | |
| WO2013033194A1 (en) | Levothyroxine formulations | |
| PL196604B1 (pl) | Kompozycja farmaceutyczna oraz klarowny roztwór farmaceutyczny do wstrzykiwań | |
| JP5325779B2 (ja) | 医薬組成物 | |
| CA2551493C (fr) | Composition pharmaceutique de vinflunine destinee a une administration parenterale, procede de preparation et utilisation | |
| CA2119270A1 (fr) | Sels de sparfloxacine et solutions les contenant | |
| FR2653998A1 (fr) | Solution injectable et procede pour la preparer. | |
| JP3917820B2 (ja) | オザグレルナトリウム含有注射液およびその安定化方法 | |
| FR2561522A1 (fr) | Solution injectable, notamment pour le traitement de la cetose et son procede de preparation | |
| JP2007106736A (ja) | 注射用の医薬組成物 | |
| OA10033A (en) | Solution hypertonique de cisplatine | |
| KR100396115B1 (ko) | 고농도의아세트아미노펜및소청룡탕엑기스를함유하는안정한액상제제및그제조방법 | |
| BE887220A (fr) | Compositions antitumeurs | |
| JP2007077060A (ja) | 注射用の医薬組成物 | |
| JP2007077059A (ja) | 注射用の医薬組成物 | |
| JP2007091674A (ja) | 注射用の医薬組成物 | |
| JPH01221312A (ja) | 脂溶性物質含有内服液 | |
| JPS6340166B2 (enExample) | ||
| HU211477A9 (hu) | Bisz-indol-alkaloid-sót tartalmazó injekciós oldat | |
| BE530825A (enExample) | ||
| JP2007191417A (ja) | 医薬用の組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Effective date: 20041130 |
|
| RE | Patent lapsed |
Effective date: 20041130 |